Je was op zoek naar: spondolite alchilosante (Italiaans - Engels)

145 durante gli studi clinici in soggetti trattati con dosi approvate di etanercept sino a 12 mesi, le quantità cumulative di anticorpi anti-etanercept erano approssimativamente del 6% nei soggetti con artrite reumatoide, 7,5% in soggetti con artrite psoriasica, 2,0% in soggetti con spondilite alchilosante, 7% in soggetti con psoriasi e 3% in soggetti con artrite giovanile idiopatica.
137 in subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% of subjects with psoriatic arthritis, 2.0% of subjects with ankylosing spondylitis, 7% of subjects with psoriasis, and 3% of subjects with juvenile idiopathic arthritis.